Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC291 in severe relapsed or refractory autoimmune diseases
NCT06294236Phase 1Active, not recruiting
- Sponsor
- Sana Biotechnology
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC291 in systemic lupus erythematosus (SLE), lupus nephritis (LN), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and 2 more (3 cohorts), sponsored by Sana Biotechnology. Primary endpoint: Safety and Tolerability of SC291 at 24 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
SC291
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT06294236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294236.